TREATING INFLAMMATORY BOWEL DISEASES THROUGH BLOCKING P2Y6 RECEPTOR

Extracellular nucleotides can favour inflammatory diseases via the activation of P2 receptors. The proinflammatory P2Y6 is the dominant nucleotide receptor in human and murine intestinal epithelial cells (IEC) and its expression increases during inflammation. Interestingly, we found that the blockade of P2Y6 totally prevented inflammation in the murine DSS model. This project will show whether and how the blockade of P2Y6 signaling in IEC can reduce, or even prevent, mucosal inflammation. This represents a new mechanism of regulation of intestinal inflammation that we anticipate can be targeted for the treatment of IBD patients. At the end of this project, Inception will have the expertise of a method for identifying a candidate compound for treating, reducing or preventing chronic inflammatory bowel diseases.

Faculty Supervisor:

Jean Sévigny

Student:

Mabrouka Salem

Partner:

Inception Sciences Canada

Discipline:

Medicine

Sector:

Medical devices

University:

Program: